CAR spacers: not just filling space
Date
2024
Authors
Brown, M.P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Molecular Therapy, 2024; 32(10):3207-3208
Statement of Responsibility
Conference Name
Abstract
A growing and sizable literature indicates that the chimeric antigen receptor (CAR)-T cell spacer is not merely an inert protein sequence between the binding ectodomain and the transmembrane component of the CAR molecule. CAR spacers have important structural and functional properties. Although spacers are not an integral part of the intracellular signaling machinery, they may, as illustrated in this issue of Molecular Therapy, have an indirect effect on cellular signaling outputs.1 Kua et al. show that a novel 25-mer spacer derived from the extracellular domain of the T cell co-stimulatory molecule 4-1BB maintained the potency of CD30-directed CAR-T cell killing while resulting in lower levels of inflammatory cytokines, unlike the original wild-type immunoglobulin (Ig)G1 spacer. Further comparative studies should elucidate the potential clinical utility of this novel CAR spacer.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.